181 related articles for article (PubMed ID: 29951083)
1. Kynurenine 3-Monooxygenase Gene Associated With Nicotine Initiation and Addiction: Analysis of Novel Regulatory Features at 5' and 3'-Regions.
Aziz HA; Abdel-Salam AG; Al-Obaide MAI; Alobydi HW; Al-Humaish S
Front Genet; 2018; 9():198. PubMed ID: 29951083
[TBL] [Abstract][Full Text] [Related]
2. Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid.
Mori Y; Mouri A; Kunisawa K; Hirakawa M; Kubota H; Kosuge A; Niijima M; Hasegawa M; Kurahashi H; Murakami R; Hoshi M; Nakano T; Fujigaki S; Fujigaki H; Yamamoto Y; Nabeshima T; Saito K
Behav Brain Res; 2021 May; 405():113191. PubMed ID: 33607168
[TBL] [Abstract][Full Text] [Related]
3. [Diagnoses and new therapeutic strategy focused on physiological alteration of tryptophan metabolism].
Mouri A; Hasegawa M; Kunisawa K; Saito K; Nabeshima T
Nihon Yakurigaku Zasshi; 2023 May; 158(3):233-237. PubMed ID: 36990795
[TBL] [Abstract][Full Text] [Related]
4. Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.
Erhardt S; Pocivavsek A; Repici M; Liu XC; Imbeault S; Maddison DC; Thomas MAR; Smalley JL; Larsson MK; Muchowski PJ; Giorgini F; Schwarcz R
Biol Psychiatry; 2017 Nov; 82(10):756-765. PubMed ID: 28187857
[TBL] [Abstract][Full Text] [Related]
5. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.
Wonodi I; Stine OC; Sathyasaikumar KV; Roberts RC; Mitchell BD; Hong LE; Kajii Y; Thaker GK; Schwarcz R
Arch Gen Psychiatry; 2011 Jul; 68(7):665-74. PubMed ID: 21727251
[TBL] [Abstract][Full Text] [Related]
6. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain.
Laumet G; Zhou W; Dantzer R; Edralin JD; Huo X; Budac DP; O'Connor JC; Lee AW; Heijnen CJ; Kavelaars A
Brain Behav Immun; 2017 Nov; 66():94-102. PubMed ID: 28709913
[TBL] [Abstract][Full Text] [Related]
8. Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
Tashiro T; Murakami Y; Mouri A; Imamura Y; Nabeshima T; Yamamoto Y; Saito K
Behav Brain Res; 2017 Jan; 317():279-285. PubMed ID: 27693848
[TBL] [Abstract][Full Text] [Related]
9. Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.
Oxenkrug G; van der Hart M; Roeser J; Summergrad P
Integr Clin Med; 2017; 1(1):. PubMed ID: 28748226
[TBL] [Abstract][Full Text] [Related]
10. Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.
Parrott JM; O'Connor JC
Front Psychiatry; 2015; 6():116. PubMed ID: 26347662
[TBL] [Abstract][Full Text] [Related]
11. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.
Tufvesson-Alm M; Schwieler L; Schwarcz R; Goiny M; Erhardt S; Engberg G
Neuropharmacology; 2018 Aug; 138():130-139. PubMed ID: 29879409
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Enzyme Activity in the Kynurenine Pathway by Kynurenine Monooxygenase Inhibition.
Phillips RS; Iradukunda EC; Hughes T; Bowen JP
Front Mol Biosci; 2019; 6():3. PubMed ID: 30800661
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the wild-type and mutant genes encoding the enzyme kynurenine monooxygenase of the yellow fever mosquito, Aedes aegypti.
Han Q; Calvo E; Marinotti O; Fang J; Rizzi M; James AA; Li J
Insect Mol Biol; 2003 Oct; 12(5):483-90. PubMed ID: 12974953
[TBL] [Abstract][Full Text] [Related]
14. Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.
Wonodi I; McMahon RP; Krishna N; Mitchell BD; Liu J; Glassman M; Hong LE; Gold JM
Schizophr Res; 2014 Dec; 160(1-3):80-7. PubMed ID: 25464917
[TBL] [Abstract][Full Text] [Related]
15. Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.
Zhang S; Collier MEW; Heyes DJ; Giorgini F; Scrutton NS
Arch Biochem Biophys; 2021 Jan; 697():108702. PubMed ID: 33275878
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model.
Rojewska E; Piotrowska A; Makuch W; Przewlocka B; Mika J
Neuropharmacology; 2016 Mar; 102():80-91. PubMed ID: 26524415
[TBL] [Abstract][Full Text] [Related]
17. Structural property of regulatory elements in human promoters.
Cao XQ; Zeng J; Yan H
Phys Rev E Stat Nonlin Soft Matter Phys; 2008 Apr; 77(4 Pt 1):041908. PubMed ID: 18517657
[TBL] [Abstract][Full Text] [Related]
18. The kynurenine pathway in schizophrenia and bipolar disorder.
Erhardt S; Schwieler L; Imbeault S; Engberg G
Neuropharmacology; 2017 Jan; 112(Pt B):297-306. PubMed ID: 27245499
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model.
Rojewska E; Ciapała K; Piotrowska A; Makuch W; Mika J
Front Pharmacol; 2018; 9():724. PubMed ID: 30050435
[TBL] [Abstract][Full Text] [Related]
20. Absence of kynurenine 3-monooxygenase reduces mortality of acute viral myocarditis in mice.
Kubo H; Hoshi M; Mouri A; Tashita C; Yamamoto Y; Nabeshima T; Saito K
Immunol Lett; 2017 Jan; 181():94-100. PubMed ID: 27889626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
